MED

Over the past six months, Medifast's stock price has declined due to weaker quarterly results, including a decrease in active earning OPTAVIA coaches and a decline in revenue. The adoption of GLP-1 weight-loss medications has pressured client acquisition. However, the stock saw a surge following its Q1 2026 earnings report due to cost-cutting efforts, a strong balance sheet, and a long-term transformation strategy towards metabolic health. Medifast plans to launch a new metabolic health system in July.